Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Stock Information for Nxu Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nxu Inc.

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.